Compare Gartner Inc (IT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Viatris Inc — how do they compare? Gartner Inc trades at $186.29 (market cap $11.83B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.95% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| IT | VTRS | |
|---|---|---|
Market Cap | $11.83B | $18.69B |
Sector | Technology | Health |
52-Week High | $264.09 | $17.86 |
52-Week Low | $125.68 | $9.49 |
Enterprise Value | $13.57B | $30.80B |
Dividend Yield | — | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
